MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Rhea-AI Summary
MAIA (NYSE American: MAIA) reported that eight patients in Parts A and B of its Phase 2 THIO-101 trial for non-small cell lung cancer showed overall survival beyond two years after treatment with ateganosine sequenced with cemiplimab, with no subsequent lines of therapy.
The poster presented March 27, 2026 highlighted one 3L patient at 33 months and two dozen 2L patients with survival over 30 months; THIO-101 treated 79 patients total and Part C is enrolling up to 48 participants in Asia and Europe.
Positive
- Eight patients with overall survival >24 months in Phase 2 THIO-101
- One 3L patient with 33 months OS versus expected 5.8 months
- Twenty-four 2L patients with OS >30 months versus 10.5 months SOC
- THIO-101 treated 79 patients across Parts A and B
- Part C expansion enrolling up to 48 participants in Asia and Europe
Negative
- Results reported for only 8 of 79 Phase 2 patients
- Five of the eight patients have survival follow-up ongoing
Key Figures
Market Reality Check
Peers on Argus
Peer action is mixed: DTIL up 4.24%, while CUE and QNTM are down roughly 3.05–3.27% (median about -3.2%). MAIA’s own intraday direction is not specified, so linkage to sector rotation cannot be determined.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Phase 3 progress | Positive | +12.0% | Phase 3 momentum and Fast Track designation in 3L NSCLC. |
| Dec 11 | Phase 3 initiation | Positive | +18.8% | Pivotal Phase 3 initiation with strong prior Phase 2 data. |
| Dec 11 | First patient dosed | Positive | +18.8% | First patient dosed in THIO-104 Phase 3 NSCLC trial. |
| Oct 23 | 30-month survival data | Positive | +7.3% | ESMO poster detailing 30-month survival in THIO-101. |
| Sep 24 | NIH grant & OS data | Positive | +4.6% | $2.3M NIH grant and improved median OS in THIO-101. |
Clinical trial updates have consistently coincided with positive one-day moves, suggesting the stock has historically reacted favorably to ateganosine data releases.
Across prior five clinical trial–tagged events since September 2025, MAIA highlighted ateganosine’s telomere‑targeting profile, Phase 2 THIO‑101 survival data, and the start of pivotal Phase 3 THIO‑104. Those disclosures produced one-day moves between roughly +4.6% and +18.8%. The current ELCC update extends that narrative by emphasizing longer-term overall survival beyond two years in NSCLC patients previously treated with checkpoint inhibitors.
Historical Comparison
Prior clinical trial updates for ateganosine produced an average one-day move of about 12.33%. Like those, this ELCC poster extends THIO-101 survival data, reinforcing a pattern of market sensitivity to NSCLC outcomes.
Clinical updates trace a path from early THIO-101 survival signals and NIH funding through the initiation of pivotal THIO-104. The current ELCC poster adds longer-term OS beyond two years in NSCLC patients previously treated with checkpoint inhibitors, building on earlier THIO-101 survival disclosures.
Market Pulse Summary
This announcement highlights longer-term overall survival beyond two years in eight NSCLC patients from the THIO‑101 Phase 2 trial, including a third-line case at 33 months versus an expected 5.8 months. These data add to prior 30‑month survival and NIH‑backed expansion of the study. Investors may monitor forthcoming THIO‑101 Part C enrollment, additional durability readouts, and how these results correlate with the pivotal THIO‑104 Phase 3 trial outcomes.
Key Terms
overall survival medical
phase 2 medical
phase 3 pivotal trial medical
checkpoint inhibitor medical
immunotherapies medical
non-small cell lung cancer medical
AI-generated analysis. Not financial advice.
Potential breakthrough therapeutic targets
CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a poster presented on March 27, 2026, at the European Lung Cancer Congress 2026 (ELCC), a premier thoracic oncology forum held March 25-28, 2026, in Copenhagen, Denmark.
MAIA reports overall survival (OS) beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of its ongoing Phase 2 THIO-101 clinical trial in non-small cell lung cancer (NSCLC). The patients did not receive subsequent lines of therapy.
The eight patients featured in the poster include:
- 1 patient in third-line (3L) therapy with survival of 33 months. Expected survival in this heavily pre-treated population is 5.8 months.2
- 4 patients in 2L therapy with survival over 30 months. Documented OS for standard of care treatment (chemotherapy or checkpoint inhibitors alone) in second-line (2L) therapy is 10.5 months.3
- All patients have failed previous treatment (prior to THIO-101) with a checkpoint inhibitor (CPI) alone.
- All patients completed 29-34 cycles of therapy, except for 1 patient who completed 2 cycles of therapy with survival follow-up of 725 off therapy.
- 5 of the 8 patients have survival follow-up ongoing.
“It’s very encouraging to see such outstanding survival from these patients extending beyond our 24-month trial protocol and without any subsequent treatment. OS surpassing two-years bodes well as we continue to monitor patients in our ongoing Phase 3 pivotal trial and in THIO-101 Part C,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “These results illuminate ateganosine’s valuable role in targeting telomeres to eliminate NSCLC tumor cells and support this treatment—ateganosine sequenced by a CPI—as a potential breakthrough therapeutic option for NSCLC.”
THIO-101 treated 79 patients in Parts A and B of the trial. The Part C expansion is currently enrolling up to 48 participants in Asia and Europe. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population.
MAIA’s ELCC poster is available on MAIA’s website at maiabiotech.com/publications.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About THIO-101 Phase 2 Clinical Trial
THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
1 Immune Checkpoint Inhibitors Market Analysis by Mordor Intelligence, July 2025
2 Girard N, et al. J Thorac Onc 2009;12:1544-1549
3 https://clinicaltrials.gov/study/NCT01168973?tab=results
FAQ
What survival outcomes did MAIA (MAIA) report at ELCC on March 27, 2026?
How many patients were treated in MAIA's THIO-101 Parts A and B and who were included?
What is the status of MAIA's THIO-101 Part C enrollment and locations as of March 31, 2026?
Did the eight patients receive further therapy after THIO-101 treatment, according to MAIA?
What safety information did MAIA provide about ateganosine followed by cemiplimab in THIO-101?
How many of the eight long-term survivors have ongoing follow-up in MAIA's report?
